Qian Dong

机构：Anhui Medical University, University of Michigan, Second Affiliated Hospital of Anhui Medical University · ORCID：0000-0002-1038-2116

发表论文 260 篇 · 总被引 6557 次 · h-index 39

代表论文

• HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy (2023 · Journal of Clinical Oncology · 被引 245)
• Application of Improved Robot-assisted Laparoscopic Telesurgery with 5G Technology in Urology (2022 · European Urology · 被引 131)
• Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78 (2023 · Proceedings of the National Academy of Sciences · 被引 40)
• HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR -mutated NSCLC (2023 · Future Oncology · 被引 27)
• Stable Cox regression for survival analysis under distribution shifts (2024 · Nature Machine Intelligence · 被引 23)
• Chemotherapy induces ACE2 expression in breast cancer via the ROS-AKT-HIF-1α signaling pathway: a potential prognostic marker for breast cancer patients receiving chemotherapy (2022 · Journal of Translational Medicine · 被引 18)